GLP-1 Questions People Ask Most (and Straight Answers)

Appeal, and get the reason in writing first. Insurers have to tell you why they denied a claim or ended coverage, and how to dispute it. You have 180 days from the denial notice to file an internal appeal; if the plan still says no, you can ask for an independent external review within 4 months of its final decision.

The reason decides the next step. A missing prior authorization or missing records can be fixed by your prescriber. A plan that excludes weight-loss drugs is common: in KFF's 2025 survey, only 19% of firms with 200 or more workers covered GLP-1s for weight loss. Then the realistic routes are the manufacturers' self-pay programs or another plan at open enrollment. See what to do when insurance says no and GLP-1 cost by route.

Sources: HealthCare.gov: internal appeals · HealthCare.gov: external review · KFF 2025 Employer Health Benefits Survey

Link to this answer

Paying cash, Zepbound costs $299–449 a month from LillyDirect, depending on the dose, and Wegovy pens cost $349–399 a month from NovoCare Pharmacy. These are the manufacturers' own self-pay prices; each shows the date it was last confirmed on the maker's page. Last known price, Oct 7, 2026 — may have changed · confirm on LillyDirect; Oct 26, 2026 · novocare.com

The $25 copay offer is a different program: it needs commercial insurance that covers the drug, so it does not help if you are uninsured or your plan excludes it. Compounded semaglutide and tirzepatide cost less but have no FDA approval, and the FDA has received reports of dosing errors with compounded injections. Our GLP-1 cost by route page lists every option with its monthly price, its one-year total and the cost per pound lost, and is re-checked every week. Last known price, Oct 7, 2026 — may have changed · confirm on LillyDirect

Sources: LillyDirect: Zepbound self-pay · NovoCare Pharmacy: Wegovy · FDA: concerns with unapproved GLP-1 drugs

Link to this answer

For many people on Part D, yes, for now. The Medicare GLP-1 Bridge runs from July 1, 2026 to December 31, 2027: if you have Part D drug coverage, meet one of three BMI-based criteria and your plan does not already cover the drug for you, you can get Wegovy, Foundayo or the Zepbound KwikPen for a $50 monthly copay. Zepbound vials are not included. Price checked Oct 25, 2026 · medicare.gov

People with type 2 diabetes, moderate-to-severe sleep apnea or MASH go through their regular Part D plan instead. There is no separate sign-up: your prescriber sends the prescription, and the pharmacy starts the prior authorization. Our Medicare GLP-1 Bridge guide has a five-question eligibility check and what to do if you do not qualify.

Sources: Medicare.gov: weight-loss drugs · CMS: Medicare GLP-1 Bridge, information for providers

Link to this answer

They are the most common side effects, and they usually ease with time. On the FDA labels, 44% of people on Wegovy had nausea (16% on placebo), and 25–29% on Zepbound (8% on placebo). In the trials, stomach symptoms were mostly mild to moderate and clustered around dose increases.

The joint nutrition advisory from four obesity and nutrition societies suggests smaller, more frequent meals and avoiding fatty food while symptoms settle, and adds that alcohol can make nausea and reflux worse. Sulfur-smelling burps are listed on both labels as belching. Vomiting or diarrhea that stops you keeping fluids down can dehydrate you and harm the kidneys, and severe stomach pain that will not go away, sometimes reaching the back, needs a call to your prescriber right away. Bland, low-fat recipes help on bad days.

Sources: FDA label: Wegovy (DailyMed) · FDA label: Zepbound (DailyMed) · SURMOUNT-1 (NEJM, 2022) · Nutritional priorities to support GLP-1 therapy (Obesity Pillars, 2025)

Link to this answer

Constipation usually means fewer than three bowel movements a week, or stools that are hard and painful to pass. It is common on these drugs: 24% of people on Wegovy reported it (11% on placebo), and 11–17% on Zepbound (5% on placebo).

The NIH's first steps are fiber from food or a supplement, more water and other fluids as fiber goes up, and regular physical activity; adults need roughly 22 to 34 grams of fiber a day. The GLP-1 nutrition advisory says food and fluids alone often are not enough, so ask your prescriber which over-the-counter laxative suits you. The labels say to tell your prescriber about stomach problems that are severe or will not go away. Our recipe library has a high-fiber filter.

Sources: NIDDK: constipation, definition and facts · NIDDK: treatment for constipation · FDA label: Wegovy (DailyMed) · FDA label: Zepbound (DailyMed)

Link to this answer

Hair loss is a listed side effect, and the Zepbound label ties it to the weight loss itself rather than to the drug directly. It was reported by 3% of people on Wegovy and 4–5% on Zepbound, against 1% on placebo, and far more often in women than men (7.1% vs 0.5% on Zepbound). In those Zepbound trials, nobody on the drug stopped because of it.

The GLP-1 nutrition advisory lists excessive hair loss among the signs that eating too little is causing a nutrient shortfall, alongside unusual fatigue and muscle weakness. So the practical checks are enough protein and calories, and a conversation with your prescriber about blood tests if it is heavy. Our protein calculator gives a daily target.

Sources: FDA label: Zepbound (DailyMed) · FDA label: Wegovy (DailyMed) · Nutritional priorities to support GLP-1 therapy (Obesity Pillars, 2025)

Link to this answer

Tiredness is a listed side effect, though it affects a minority: 11% of people on Wegovy (5% on placebo) and 5–7% on Zepbound (3% on placebo) in the label trials. The labels group it with weakness, lethargy and malaise.

Two causes are worth ruling out. Eating very little can leave you short of energy and nutrients; the GLP-1 nutrition advisory names fatigue beyond what you would expect as a sign of that. And vomiting or diarrhea can dehydrate you, which the labels link to kidney problems and, in some people, low blood pressure. So check fluids, protein and total food first. If the tiredness is heavy, lasts, or comes with dizziness or fainting, talk to your prescriber rather than changing the dose yourself. The protein calculator helps with the food side.

Sources: FDA label: Wegovy (DailyMed) · FDA label: Zepbound (DailyMed) · Nutritional priorities to support GLP-1 therapy (Obesity Pillars, 2025)

Link to this answer

Not according to the labels. Both FDA labels say the abdomen, thigh and upper arm give similar drug levels in the blood, and the Wegovy label adds that you can change the site without changing the dose. What both labels do ask is that you rotate the site with every dose.

Redness, itching, bruising or a small lump where you injected are known reactions: 6–8% of people on Zepbound reported one (2% on placebo), and 1.4% on Wegovy (1% on placebo). Swelling of the face, lips or throat, trouble breathing or a spreading rash is different: that can be an allergic reaction and needs urgent care. If you think one site works better for you, bring your weekly weights to your prescriber; the tracker keeps them in one place.

Sources: FDA label: Zepbound (DailyMed) · FDA label: Wegovy (DailyMed)

Link to this answer

A common target during active weight loss is 1.2 to 1.6 grams per kilogram of goal weight a day (current weight if you're already near goal). That range comes from the joint advisory of four obesity and nutrition societies on GLP-1 treatment, which also says protein should not fall below 0.4 to 0.5 g/kg and that long stretches above 2 g/kg are best avoided.

If you have a lot to lose, use your goal weight: current weight gives a number that overshoots what muscle needs and is hard to eat on a suppressed appetite. When appetite is low, eat the protein part of a meal first and spread it across the day. Our protein calculator works out your range, and every recipe here has at least 25 g in one serving.

Sources: Nutritional priorities to support GLP-1 therapy (Obesity Pillars, 2025)

Link to this answer

You do not have to count, but it is worth checking that you are not eating far too little. The drug makes you eat less on its own; the risk is undershooting. The GLP-1 nutrition advisory warns that very low intakes make it hard to get enough vitamins and minerals, and lists the warning signs: fatigue beyond what you would expect, excessive hair loss, flaky or itchy skin, muscle weakness, poor wound healing and unusual bruising.

A few days of logging now and then is a simple check on protein and total food. The labels pair the drug with a reduced-calorie diet and more physical activity, not with a set number. Our calorie calculator gives a floor and a target, and your prescriber or a dietitian can set one for you.

Sources: Nutritional priorities to support GLP-1 therapy (Obesity Pillars, 2025) · FDA label: Zepbound (DailyMed)

Link to this answer

Small portions built around protein, with fiber and fluids, and less fat on queasy days. That is the core of the joint GLP-1 nutrition advisory: protect protein and nutrients as total intake falls, eat smaller and more frequent meals, and keep large or greasy meals to a minimum because they can worsen nausea.

In practice that means things like Greek yogurt, eggs, cottage cheese, fish, chicken, beans and lentils, soups, and drinks such as milk or a protein shake when a plate will not go down. Our 20 GLP-1 recipes are single servings with at least 25 g of protein, and can be filtered for nausea days, low appetite, high fiber and no cooking.

Sources: Nutritional priorities to support GLP-1 therapy (Obesity Pillars, 2025)

Link to this answer

Some lean mass, meaning muscle and other non-fat tissue, goes with any large weight loss. Body-composition studies suggest roughly 25–35% of weight lost can be lean mass, varying by drug and study. A 2026 meta-analysis estimated about 25% for tirzepatide and about 35% for semaglutide. The joint GLP-1 nutrition advisory notes that the loss tracks how much weight comes off, as after bariatric surgery or very low-calorie diets. Adequate protein and resistance training may help preserve it.

The joint GLP-1 nutrition advisory recommends prescribing these drugs together with a structured exercise program that includes resistance training, and protein of about 1.2 to 1.6 g per kg a day during active loss, counted on goal weight if you have a lot to lose. Lifting weights, resistance bands or body-weight exercises all count. Our protein calculator gives your range.

Sources: Nutritional priorities to support GLP-1 therapy (Obesity Pillars, 2025) · Lean mass changes with incretin therapy: meta-analysis (Diabetes Obes Metab, 2026)

Link to this answer

Slowing down is built into the curve: in the trials, weight loss is fastest early on and levels off later, so a slower month is expected rather than a sign that the drug stopped working. STEP 1 averaged 14.9% at 68 weeks on Wegovy and SURMOUNT-1 20.9% at 72 weeks on Zepbound 15 mg, but those are averages. People lose at very different rates, and not everyone reaches 5%.

Before calling it a plateau, look at several weeks of weigh-ins rather than single days. Then check the basics: protein, total intake and activity. Whether a dose change makes sense is a question for your prescriber, who knows your history. Our curve calculator shows where you sit against the trial average for your week, and the plateau check reads your recent trend.

Sources: STEP 1 (NEJM, 2021) · SURMOUNT-1 (NEJM, 2022)

Link to this answer

The first weeks are a starting dose, so small early losses are normal. Zepbound starts at 2.5 mg for 4 weeks, and the label says that dose is only for starting, not for long-term treatment; Wegovy steps up every 4 weeks from 0.25 mg. The large results in the trials came over more than a year.

Most people do respond: in SURMOUNT-1, 85–91% of people on Zepbound lost at least 5% by week 72, and 86.4% on Wegovy in STEP 1. That also means a minority did not, so if you have been on a full dose for months with little change, bring your weekly weights to your prescriber and talk through the options. Our curve calculator shows the trial average for your week and starting weight.

Sources: FDA label: Zepbound (DailyMed) · FDA label: Wegovy (DailyMed) · SURMOUNT-1 (NEJM, 2022) · STEP 1 (NEJM, 2021)

Link to this answer

That is a decision for your prescriber, and the label gives them room either way. For Zepbound, the dose goes up in 2.5 mg steps after at least 4 weeks on the current one, and the label lists 5 mg, 10 mg and 15 mg as maintenance doses, chosen by how well you respond and how well you tolerate it. Wegovy steps up every 4 weeks to its usual maintenance dose of 2.4 mg.

Higher doses did lose more on average: in SURMOUNT-1, 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg after 72 weeks. Side effects also cluster around each increase. Bring your weekly weights and how you are feeling to the appointment; our dose tracker keeps both in one place.

Sources: FDA label: Zepbound (DailyMed) · FDA label: Wegovy (DailyMed) · SURMOUNT-1 (NEJM, 2022)

Link to this answer

Most people who stop regain much of the weight, which is why both labels describe them as treatment to reduce weight and maintain the reduction long term. In the STEP 1 extension, people who stopped Wegovy regained two-thirds of the weight they had lost within a year. In SURMOUNT-4, people switched from Zepbound to placebo regained 14.0% of their body weight over a year, while those who stayed on lost another 5.5%.

In the STEP 1 extension the lifestyle program ended along with the drug, so treat these averages as a realistic default rather than a certainty. Whether to stop, taper or stay on is a decision to make with your prescriber. If you do stop, our free 16-week maintain plan sets a warning line and a weekly weigh-in so regain is caught early.

Sources: STEP 1 extension (Diabetes Obes Metab, 2022) · SURMOUNT-4 (JAMA, 2024) · FDA label: Zepbound (DailyMed)

Link to this answer

Each label has its own rule, and your prescriber should know about any gap. The Zepbound label: take a missed dose within 4 days (96 hours); after that, skip it and take the next dose on your usual day. The Wegovy injection label: take it if your next dose is more than 2 days away, otherwise skip it; if you miss 2 or more doses in a row, it says to restart at a lower dose to avoid stomach side effects. The Foundayo label says not to double up.

A planned break for travel, surgery or a procedure is worth raising with your prescriber in advance, and both labels ask you to tell your healthcare providers about any planned surgery or procedure. If a break turns into stopping, the maintain plan helps you watch the scale week by week.

Sources: FDA label: Zepbound (DailyMed) · FDA label: Wegovy (DailyMed) · FDA label: Foundayo (DailyMed)

Link to this answer

Switching is a prescriber decision, and there is no official conversion table between the two. Neither label gives a starting dose for someone coming from the other drug, so your prescriber picks one, usually weighing how well you tolerated the last drug and how you responded to it.

The one head-to-head trial, SURMOUNT-5, favoured tirzepatide: an average 20.2% weight loss on Zepbound against 13.7% on Wegovy after 72 weeks, with stomach side effects the most common complaint on both. Averages do not predict any one person. Our drug comparison sets out trial results, dosing, side effects and self-pay prices side by side for your appointment.

Sources: SURMOUNT-5 (NEJM, 2025) · FDA label: Zepbound (DailyMed) · FDA label: Wegovy (DailyMed)

Link to this answer

Same medicine, different packaging. The Zepbound label lists four forms: single-dose pens and single-dose vials (one injection each), and multi-dose vials and the KwikPen, which each hold 4 weekly doses. Vials are used with a separate syringe and needle; the pens are injection devices.

The differences that matter are practical. Which forms your pharmacy, plan or program covers varies: the Medicare GLP-1 Bridge, for example, covers the KwikPen but not vials. LillyDirect's self-pay prices are $299–449 a month by dose. If you change forms, ask your pharmacist to walk you through the new device, since the steps are not the same. See cost by route for current prices by form. Last known price, Oct 7, 2026 — may have changed · confirm on LillyDirect

Sources: FDA label: Zepbound (DailyMed) · CMS: Medicare GLP-1 Bridge, information for providers · LillyDirect: Zepbound self-pay

Link to this answer

On trial averages, the pills lose less than the strongest injections but a meaningful amount. The Wegovy pill (oral semaglutide, approved Dec 22, 2025 for adults; 25 mg once daily maintenance) averaged 13.6% at 64 weeks in OASIS 4, close to the 14.9% for Wegovy injections in STEP 1. It is the same molecule as the injection, a different product from Rybelsus. Foundayo (orforglipron) averaged 7.4% to 11.1% at 72 weeks in ATTAIN-1, depending on the dose (Foundayo prescribing information), and Zepbound injections 20.9% at the top dose.

The routines differ. The Wegovy pill is taken each morning on an empty stomach with up to 4 ounces of water, then nothing else for 30 minutes; Foundayo can be taken with or without food. These are separate trials, not head-to-head, so ask your prescriber which fits. Our drug comparison lines them up.

Sources: OASIS 4 (NEJM, 2025) · ATTAIN-1 (NEJM, 2025) · FDA label: Wegovy (DailyMed) · FDA label: Foundayo (DailyMed)

Link to this answer